Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study
| Autor: | Kouichi Ito, Reuben M. Valenzuela, Mark Rametta, Suhayl Dhib-Jalbut, Sumandeep Sumandeep, Payal Patel |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Abortion Habitual Multiple Sclerosis Adolescent medicine.medical_treatment Immunology Vascular Cell Adhesion Molecule-1 Immune markers Enzyme-Linked Immunosorbent Assay Disability Evaluation Young Adult Immune system Text mining Adjuvants Immunologic Neurotrophic factors medicine Immunology and Allergy Humans In patient Tissue Inhibitor of Metalloproteinase-2 business.industry Multiple sclerosis Interferon beta-1b Interferon-beta Middle Aged medicine.disease Cytokine Neurology Cytokines Matrix Metalloproteinase 2 Female Neurology (clinical) business |
| Zdroj: | Journal of neuroimmunology. 254(1-2) |
| ISSN: | 1872-8421 |
| Popis: | We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12 months. IL-17 levels were significantly higher at Month 6 ( p = 0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 ( p = 0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8 + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect